Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab Improve Survival in CNS Lymphoma?

Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response and survival rates – questioning the role of rituximab in this patient population.

SHARE